Bull Pharmachem Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Bull Pharmachem Pharmaceutical Export Portfolio Dataset — 3 Products, $510.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bull Pharmachem — Pharmaceutical Exporter Profile (2026) | 3 Products, $510.2K Trade | TransData Nexus

Bull Pharmachem

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $510.2K Total Trade · DGFT Verified

Bull Pharmachem is an Indian pharmaceutical exporter with a total trade value of $510.2K across 3 products in 3 therapeutic categories. Based on 170 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ivermectin ($412.0K), Raltegravir ($82.1K), Ibrutinib ($16.1K).

Bull Pharmachem — Export Portfolio & Destination Treemap

Bull Pharmachem pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Bull Pharmachem? — Company Overview & Market Position

Established in 2014, Bull Pharmachem is a Mumbai-based exporter specializing in a diverse range of pharmaceutical products, including anti-cancer medicines, Ivermectin tablets, Sildenafil tablets, and Osimertinib tablets. The company operates as a sole proprietorship under the leadership of Mr. Parag Jain, who serves as the Managing Director and CEO. With an annual turnover ranging from ₹10 to ₹25 crore (approximately $1.3 to $3.3 million USD), Bull Pharmachem employs between 11 to 25 individuals. The company's registered office is located at No. 64C, Dhan Sadan Co-operative Housing Society, 2nd Floor, Kalbadevi, Mumbai - 400002, Maharashtra, India. Their official website is www.bullpharmachem.com.

What Does Bull Pharmachem Export? — Product Portfolio Analysis

Top Products by Export Value

1Ivermectin$412.0K 2Raltegravir$82.1K

Product Portfolio — Top 3 by Export Value

Bull Pharmachem exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ivermectin	Antimalarial & Antiparasitic	$412.0K	152	4.7%	5
2	Raltegravir	Antiviral & HIV Medications	$82.1K	4	1.3%	4
3	Ibrutinib	Advanced Oncology	$16.1K	14	1.6%	11

Bull Pharmachem exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $510.2K. The top category is Antimalarial & Antiparasitic (80.8% of portfolio), followed by Antiviral & HIV Medications (16.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Bull Pharmachem — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Bull Pharmachem sources its pharmaceutical products from state-of-the-art manufacturing facilities that are inspected and approved by international regulatory bodies, including WHO-GMP, USFDA, PMDA Japan, KFDA Korea, and ANVISA Brazil. These facilities are capable of handling complex and hazardous reactions, ensuring the production of high-quality medicines. The company offers a wide variety of packaging options to meet the diverse needs of its global clientele.

3Key Leadership

Mr. Parag Jain serves as the Managing Director and CEO of Bull Pharmachem. His leadership and business acumen have been instrumental in the company's growth and success in the pharmaceutical export sector. Under his guidance, the company has expanded its product portfolio and established a strong presence in international markets.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Bull Pharmachem Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Bull Pharmachem has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold approvals from the USFDA, PMDA Japan, KFDA Korea, and ANVISA Brazil, indicating compliance with stringent international standards. These approvals facilitate the company's market access and distribution in these regions. However, specific details regarding regulatory filings, approvals, and market access status in each of these countries are not publicly disclosed.

2Emerging Markets

Bull Pharmachem has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as evidenced by approvals from WHO-GMP, USFDA, PMDA Japan, KFDA Korea, and ANVISA Brazil, enhances its credibility and facilitates access to these markets. While specific details regarding WHO prequalification and other regulatory approvals in these regions are not publicly available, the company's global certifications position it favorably for market penetration.

3Geographic Strategy

Bull Pharmachem — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Bull Pharmachem's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly disclosed. The company's manufacturing facilities hold approvals from the USFDA, indicating compliance with FDA standards. However, without access to detailed regulatory filings and inspection records, a comprehensive assessment of the company's FDA status cannot be conducted.

2WHO & EU GMP

Bull Pharmachem's manufacturing facilities are approved by WHO-GMP, USFDA, PMDA Japan, KFDA Korea, and ANVISA Brazil, demonstrating compliance with international quality standards. However, specific details regarding WHO prequalification, EU GMP certificates, and EDQM status are not publicly available. The absence of publicly accessible information on these certifications limits the ability to fully assess the company's compliance with WHO and EU GMP standards.

3CDSCO & Indian Regulatory

Bull Pharmachem operates under the jurisdiction of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds a GST registration (GST No. 27AKFPJ6383E1Z2) and an Import Export Code (IEC) (0316915777), indicating compliance with Indian regulatory requirements for import and export activities. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed.

Bull Pharmachem — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical export sector, Bull Pharmachem faces competition from other Indian exporters specializing in similar therapeutic categories, such as Antimalarial & Antiparasitic, Antiviral & HIV Medications, and Advanced Oncology. While specific market share data is not publicly available, the company's focus on high-demand products like Ivermectin positions it favorably in the market. A detailed head-to-head analysis would require access to proprietary market research data, which is not publicly disclosed.

2Key Differentiators

Bull Pharmachem's key differentiators include its specialization in high-demand pharmaceutical products, such as Ivermectin, and its adherence to international quality standards, as evidenced by approvals from WHO-GMP, USFDA, PMDA Japan, KFDA Korea, and ANVISA Brazil. These factors enhance the company's credibility and appeal to international clients seeking reliable pharmaceutical suppliers.

3Strategic Position

Bull Pharmachem's current strategic direction focuses on exporting finished pharmaceutical formulations, particularly in the Antimalarial & Antiparasitic therapeutic category. The company's adherence to international quality standards and its specialization in high-demand products position it well for continued growth in the global pharmaceutical export market. Future strategic initiatives may include diversifying the product portfolio and expanding into additional therapeutic areas to mitigate concentration risks and capitalize on emerging market opportunities.

Buyer Due Diligence Brief — Evaluating Bull Pharmachem as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Bull Pharmachem has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $510K USD across 170 shipments from 2022 to 2026. The company's portfolio is concentrated in three therapeutic categories, with the top five products accounting for 100% of the export value. This concentration indicates a focused approach to product offerings. The company's adherence to international quality standards, as evidenced by approvals from WHO-GMP, USFDA, PMDA Japan, KFDA Korea, and ANVISA Brazil, enhances its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure compliance with international quality standards:

FDA Approval: Confirm that the manufacturing facilities are registered with the USFDA and that products are listed in the FDA's Drug Establishments Current Registration System (DECRS).

WHO-GMP Certification: Verify that the manufacturing facilities hold a valid WHO-GMP certificate, indicating compliance with World Health Organization Good Manufacturing Practices.

Frequently Asked Questions — Bull Pharmachem

How many pharmaceutical products does Bull Pharmachem export from India?

Bull Pharmachem exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Ivermectin ($412.0K), Raltegravir ($82.1K), Ibrutinib ($16.1K). Total export value is $510.2K.

What is Bull Pharmachem's total pharmaceutical export value?

Bull Pharmachem's total pharmaceutical export value is $510.2K, based on 170 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Bull Pharmachem cover?

Bull Pharmachem exports across 3 therapeutic categories. The largest are Antimalarial & Antiparasitic (80.8%, 1 products), Antiviral & HIV Medications (16.1%, 1 products), Advanced Oncology (3.1%, 1 products).

Get Full Bull Pharmachem Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.